TLDR: Harvard’s IBIT stake climbed 257 % to about $442.8 million in Q3. GLD holdings nearly doubled to $235 million, signalling diversification. IBIT is now Harvard’s largest disclosed position in a 13F filing. Institutional flow into Bitcoin ETFs continues despite short‑term crypto volatility. The Harvard University endowment reported an allocation of 6,813,612 shares in the IBIT (iShares Bitcoin [...] The post Harvard Makes Major Move in Bitcoin ETF Holdings appeared first on Blockonomi.TLDR: Harvard’s IBIT stake climbed 257 % to about $442.8 million in Q3. GLD holdings nearly doubled to $235 million, signalling diversification. IBIT is now Harvard’s largest disclosed position in a 13F filing. Institutional flow into Bitcoin ETFs continues despite short‑term crypto volatility. The Harvard University endowment reported an allocation of 6,813,612 shares in the IBIT (iShares Bitcoin [...] The post Harvard Makes Major Move in Bitcoin ETF Holdings appeared first on Blockonomi.

Harvard Makes Major Move in Bitcoin ETF Holdings

TLDR:

  • Harvard’s IBIT stake climbed 257 % to about $442.8 million in Q3.
  • GLD holdings nearly doubled to $235 million, signalling diversification.
  • IBIT is now Harvard’s largest disclosed position in a 13F filing.
  • Institutional flow into Bitcoin ETFs continues despite short‑term crypto volatility.

The Harvard University endowment reported an allocation of 6,813,612 shares in the IBIT (iShares Bitcoin Trust) valued at approximately $442.8 million as of September 30. That stake reflects a 257 % increase from the previously reported 1,906,000 shares at the end of June. 

Simultaneously, Harvard disclosed holding 661,391 shares in the GLD gold ETF, valued at about $235 million, a 99 % rise from 333,000 shares in June. These filings indicate a clear and substantial institutional shift in asset allocation toward both Bitcoin‑linked ETFs and gold.

Institutional shift: Harvard’s Bitcoin ETF positioning

The Q3 filing marks IBIT as Harvard’s largest single position disclosed in its 13F filing, surpassing major tech holdings in its portfolio. The quantum of shares, 6.81 million, valued at around $442.9 million, represents Harvard’s steepest increase quarter‑over‑quarter.

The gold ETF move also speaks to a defensive tilt: the GLD shares rose to 661,391 as of September 30, marking about 98.6 % growth from 333,000 shares at June end. The concurrent boost in Bitcoin and gold holdings suggests Harvard is expanding its portfolio’s exposure to alternative, non‑traditional assets.

This shift comes despite heightened volatility in the broader crypto market and sizeable outflows from spot Bitcoin ETFs in recent weeks. By choosing to increase exposure at this stage, Harvard adds a notable institutional data point for investors tracking large‑scale flows into crypto‑linked instruments.

What this means for the crypto market and edge toward Bitcoin

Harvard’s decision to markedly increase its IBIT holdings offers more than just a portfolio change; it acts as a signal to the asset‑management community. Historically, university endowments have been cautious about allocating to digital assets or crypto‑related ETFs.

By deploying hundreds of millions into IBIT, Harvard may tilt the institutional narrative around Bitcoin and crypto ETFs.

Moreover, the simultaneous strengthening of its gold position underscores an asset‑allocation strategy that blends growth potential and hedging. The gold ETF move may reflect concerns over macro risks and inflation, while the Bitcoin ETF move reflects belief in digital‑asset infrastructure or long‑term structural change.

From a market‑sentiment perspective, this large‑scale institutional allocation occurs even as retail‑driven flows face pressure. Hence, long‑term holders and institutional investors may view these filings as a stabilising sign for crypto ETFs and digital‑asset adoption curves.

The post Harvard Makes Major Move in Bitcoin ETF Holdings appeared first on Blockonomi.

Market Opportunity
Major Logo
Major Price(MAJOR)
$0.1355
$0.1355$0.1355
+4.90%
USD
Major (MAJOR) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Edges higher ahead of BoC-Fed policy outcome

Edges higher ahead of BoC-Fed policy outcome

The post Edges higher ahead of BoC-Fed policy outcome appeared on BitcoinEthereumNews.com. USD/CAD gains marginally to near 1.3760 ahead of monetary policy announcements by the Fed and the BoC. Both the Fed and the BoC are expected to lower interest rates. USD/CAD forms a Head and Shoulder chart pattern. The USD/CAD pair ticks up to near 1.3760 during the late European session on Wednesday. The Loonie pair gains marginally ahead of monetary policy outcomes by the Bank of Canada (BoC) and the Federal Reserve (Fed) during New York trading hours. Both the BoC and the Fed are expected to cut interest rates amid mounting labor market conditions in their respective economies. Inflationary pressures in the Canadian economy have cooled down, emerging as another reason behind the BoC’s dovish expectations. However, the Fed is expected to start the monetary-easing campaign despite the United States (US) inflation remaining higher. Investors will closely monitor press conferences from both Fed Chair Jerome Powell and BoC Governor Tiff Macklem to get cues about whether there will be more interest rate cuts in the remainder of the year. According to analysts from Barclays, the Fed’s latest median projections for interest rates are likely to call for three interest rate cuts by 2025. Ahead of the Fed’s monetary policy, the US Dollar Index (DXY), which tracks the Greenback’s value against six major currencies, holds onto Tuesday’s losses near 96.60. USD/CAD forms a Head and Shoulder chart pattern, which indicates a bearish reversal. The neckline of the above-mentioned chart pattern is plotted near 1.3715. The near-term trend of the pair remains bearish as it stays below the 20-day Exponential Moving Average (EMA), which trades around 1.3800. The 14-day Relative Strength Index (RSI) slides to near 40.00. A fresh bearish momentum would emerge if the RSI falls below that level. Going forward, the asset could slide towards the round level of…
Share
BitcoinEthereumNews2025/09/18 01:23